(PharmaNewsWire.Com, March 08, 2018 ) Latin America Schizoaffective Disorders Treatment Market was worth USD xx billion in 2017 and estimated to be growing at a CAGR of xx%, to reach USD xx billion by 2022. Schizoaffective Disorder is a mental disorder which is characterized by deregulated emotions and thought processes and. The diagnosis is made when the person has features of both a mood disorder—either bipolar disorder or depression, and schizophrenia but does not meet the diagnostic criteria for either alone strictly. The bipolar type is distinguished by symptoms of hypomania, mania, or mixed episode; the depressive type only by symptoms of depression. Common symptoms of the disorder include paranoid delusions, hallucinations, and disorganized thinking and speech. The onset of symptoms usually begins in young times of adulthood, presently with an uncertain lifetime prevalence since the disorder was redefined in DSM-IV. Diagnosis is based on the person's reported experiences observed behaviour.
Neurobiology, genetics, early and current environment, social, behavioural, and experiential components appear to be important contributory factors; some prescription and recreational drugs may worsen or cause symptoms. People with schizoaffective disorder are likely to have co-occurring conditions, including substance use disorder and anxiety disorders. Social problems such as long-term unemployment, homelessness and poverty are common. The average life expectancy of people with the disorder is less than those without it, due to rise of problems related to physical health from an absence of health promoting behaviours including a higher suicide rate and a sedentary lifestyle.
The driving factors of Latin America Schizoaffective Disorders Treatment market are rapidly rising sedentary life style, increasing healthcare spending, growing prevalence of chronic diseases, availability of advanced healthcare treatments and increasing awareness about schizoaffective disorders. While on the other hand, stringent regulatory approval procedures, social stigma associated with schizoaffective disorders, and lack of diagnosis at right time are some of the factors that are constraining the growth of the Latin America schizoaffective disorders treatment market.
Key points:
· Introduction
· Research Methodology
· Overview
· Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
· Market Segmentation
· Geographical Analysis
· Strategic Analysis
· Market Leaders' Analysis
· Competitive Landscape
· Expert Opinions
The Latin America Schizoaffective Disorders Treatment market is segmented based on treatment into antipsychotics, mood stabilisers, antidepressants, anticonvulsants and psychotherapy. Antipsychotics is further segmented into aripriprazole, clozapine, haloperidol, risperidone, olanzapine and others. Aripripazole has the largest market share. Mood stabilisers are further divided into divalproex, lithium and others. Anticonvulsants are further categorised into valproate, carbamazepine and others. By antidepressants, the market is divided into desvenlafaxine, fluoxetine, escitalopram and others. Escitalopram has the largest share in the segment, which is followed by fluoxetine. Psychotherapy is further segmented into group therapy, psychotherapy & counselling and others.
The Latin America Schizoaffective Disorders Treatment market is divided based on geography into Argentina, Brazil, Chile, Peru and other parts of the region. Factors such as growing healthcare spending and rising prevalence of chronic diseases is expected to drive the market growth in the region.
Some of the major players in the market are Merz Pharma GmbH & Co. KGaA., Eli Lilliy and Company, Elan Pharmaceuticals, Ciba Pharmaceuticals, Abbott Pharmaceuticals, AstraZeneca plc, and Janssen-Cilag Pty Limited.
About Market Data Forecast Market Data Forecast is a well versed market research firm catering solutions in the fields of market research, business intelligence and consulting. With a profound knowledge about the global market activities coupled with a customized approach. We render services in the most gripping markets like healthcare, agriculture and food & Beverages
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
